Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 299 of 5804
-
New cancer drug BNT3214 enters human trials for advanced tumors
Disease control Recruiting nowThis study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) wi…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can zapping the main tumor boost survival in advanced lung cancer?
Disease control Not yet recruitingFor patients with non-small cell lung cancer and more than five metastatic lesions (non-oligometastatic disease), does radical treatment of the primary lung lesion, in addition to pharmacotherapy, also provide benefits in terms of progression-free survival (PFS) and local control…
Phase: NA • Sponsor: Guizhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cord blood stem cells aim to repair hearts after attack
Disease control Not yet recruitingThis trial is a Phase II, multicenter clinical study. The purpose of this trial is to evaluate the safety and efficacy of MiSaver, a cellular therapy product, in patients who have experienced an acute myocardial infarction (AMI). Specifically, the study aims to assess the improve…
Phase: PHASE2 • Sponsor: HONYA Medical Co Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug duo aims to shrink lung tumors before surgery
Disease control Recruiting nowThe aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug duo takes on deadly brain infection
Disease control Not yet recruitingAlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity. The current trial aims to assess the plasma and CSF PK, as well as the safety and tolerability of alpibectir and three dose…
Phase: PHASE2 • Sponsor: BioVersys AG • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy aims to keep leukemia away after transplant
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell transplant (HSCT) of patients with Philadelphia chromosome…
Phase: PHASE2 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Rechallenge therapy shows promise for Tough-to-Treat colorectal cancer
Disease control Not yet recruitingThis study is a phase II, open-label, multicenter clinical trial designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed after standard therapies. The study compares a rechallenge treatment using irinotecan …
Phase: PHASE2 • Sponsor: Gruppo Oncologico Italia Meridionale • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New triple therapy aims to stall return of ovarian cancer
Disease control Not yet recruitingEfficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New HIV vaccine trial aims to boost immune control in patients on ART
⭐️ VACCINE ⭐️ Recruiting nowThe goal of this randomized clinical trial is to evaluate the safety and immunogenicity of the HIV Therapeutic DNA Vaccine (ICVAX) in participants with HIV-1 infection under antiretroviral therapy (ART). The study compares three delivery methods - Teresa -EPT I, PharmaJet Tropis,…
Phase: PHASE1 • Sponsor: Immuno Cure Holding (HK) Limited • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:07 UTC
-
Heat-and-freeze therapy plus immunotherapy aims to turn liver tumors into cancer-fighting vaccines
Disease control Recruiting nowThis study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a 3-Week radiation course beat 5 weeks for breast cancer patients with reconstruction?
Disease control Recruiting nowThis study investigates the safety and efficacy of hypofractionated radiotherapy (HFRT) versus conventional fractionated radiotherapy (CFRT) in breast cancer patients undergoing total mastectomy with prosthetic reconstruction. Study Design Population: Patients with high-risk bre…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill may keep rare lymphoma in check after chemo
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating golidocitinib as maintenance therapy in adult patients with peripheral T-cell lymphoma (PTCL) who achieved complete response (CR) or partial response (PR) after first-line systemic chem…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for patients with rare lung cancer transformation
Disease control Not yet recruitingThe primary treatment option for non-small cell lung cancer (NSCLC) adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutation is EGFR tyrosine kinase inhibitor (TKI). After a certain period of treatment with EGFR TKI, acquired resistance emerges most frequen…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Best-Link Bioscience, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowResearchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called M…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill aims to tame painful lupus skin flares
Disease control Not yet recruitingThe purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 …
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Supercharged immune cells take on advanced liver cancer
Disease control Recruiting nowThis study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
Phase: PHASE1 • Sponsor: Guangzhou FineImmune Biotechnology Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New injection could ease sleep apnea and aid weight loss
Disease control Not yet recruitingThe study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of GZR18 injection in Chinese adult obese patients with moderate-to-severe obstructive sleep apnea (OSA) who are currently using p…
Phase: PHASE3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy aims to shrink lung tumors without chemo or surgery
Disease control Recruiting nowThis is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for lung injury: drug may repair radiation and immunotherapy damage
Disease control Recruiting nowRadiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinic…
Phase: PHASE2, PHASE3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immune cells armed to hunt down hidden leukemia
Disease control Recruiting nowThe purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome …
Phase: PHASE1 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC